Car t cell therapy: CAR T-cell therapy shows activity in lymphoma despite lack of measurable disease

Disclosures: Bishop reports consultant/speaker’s bureau roles with Agios Pharmaceuticals, Celgene, CRISPR Therapeutics, Juno Therapeutics, Kite Pharma, Novartis and Optum; board of directors/advisory committee roles with Juno Therapeutics, Kite Pharma and Novartis; research funding from Juno Therapeutics, Kite Pharma and Novartis; honoraria from Agios Pharmaceuticals, Celgene, CRISPR Therapeutics, Juno Therapeutics, Kite Pharma, Novartis and Optum; and was employed by Optum. Please see the study for all other authors’ relevant financial disclosures.

Leave a Reply

Your email address will not be published. Required fields are marked *